Brachytherapy
Volume 9, Issue 1 , Pages 61-65 , January 2010

Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: The Indiana University experience

  • Achilles J. Fakiris

      Affiliations

    • Department of Radiation Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, RT 041, Indianapolis, IN 46202
    • Corresponding Author InformationCorresponding author. Tel.: +1-317-274-2524; fax: +1-317-274-2486.
    • ,
  • Mark Henderson

      Affiliations

    • Department of Radiation Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, RT 041, Indianapolis, IN 46202
    • ,
  • Simon S. Lo

      Affiliations

    • Ohio State University Medical Center, Columbus, OH
    • ,
  • Katherine Y. Look

      Affiliations

    • Department of Radiation Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, RT 041, Indianapolis, IN 46202
    • ,
  • Higinia R. Cardenes

      Affiliations

    • Department of Radiation Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, RT 041, Indianapolis, IN 46202

Received 14 January 2008 ,Revised 9 July 2008 ,Accepted 21 October 2008.

References 

  1. American Cancer Society . Cancer facts & figures 2007. Atlanta, GA: American Cancer Society; 2007;
  2. Cirisano FD, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77:55–65
  3. Hendrickson M, Ross J, Eifel P, Martinez A, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108
  4. Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin Obstet Gynecol. 1996;39:686–695
  5. Gehrig PA, Groben PA, Fowler WC, et al. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol. 2001;97:153–157
  6. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463–469
  7. Sood BM, Jones J, Gupta S, et al. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2003;57:208–216
  8. Sutton GP, Brill L, Michael H, et al. Malignant papillary lesions of the endometrium. Gynecol Oncol. 1987;27:294–304
  9. Ward BG, Wright RG, Free K. Papillary carcinomas of the endometrium. Gynecol Oncol. 1990;39:347–351
  10. Geisler JP, Geisler HE, Melton ME, et al. What staging surgery should be performed on patients with uterine papillary serous carcinoma?. Gynecol Oncol. 1999;74:465–467
  11. Bristow RE, Asrari F, Trimble EL, et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol. 2001;81:279–286
  12. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54:264–268
  13. Bancher-Todesca D, Neunteufel W, Williams KE, et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol. 1998;71:344–347
  14. Gitsch G, Friedlander ML, Wain GV, et al. Uterine papillary serous carcinoma. A clinical study. Cancer. 1995;75:2239–2243
  15. Huh WK, Powell M, Leath CA, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol. 2003;91:470–475
  16. Tay EH, Ward BG. The treatment of uterine papillary serous carcinoma (UPSC): are we doing the right thing?. Int J Gynecol Cancer. 1999;9:463–469
  17. Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;97:755–763
  18. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100:349–354
  19. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:36–44
  20. Soper JT, Berchuck A, Dodge R, et al. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. Obstet Gynecol. 1992;79:993–997
  21. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322:1021–1027
  22. Creasman WT, Disaia PJ, Blessing J, et al. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol. 1981;141:921–929
  23. Soper JT, Creasman WT, Clarke-Pearson DL, et al. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol. 1985;153:191–196
  24. Fakiris AJ, Moore DH, Reddy SR, et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study. Gynecol Oncol. 2005;96:818–823
  25. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355:1404–1411
  26. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–751
  27. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63:834–838
  28. McCormick TC, Cardenes H, Randall ME. Early-stage endometrial cancer: is intravaginal radiation therapy alone sufficient therapy?. Brachytherapy. 2002;1:61–65
  29. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: Evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 1998;69:69–73
  30. Mehta N, Yamada SD, Rotmensch J, et al. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;57:1004–1009
  31. Kato DT, Ferry JA, Goodman A, et al. Uterine papillary serous carcinoma (UPSC): A clinicopathologic study of 30 cases. Gynecol Oncol. 1995;59:384–389
  32. Jeffrey JF, Krepart GV, Lotocki RJ. Papillary serous adenocarcinoma of the endometrium. Obstet Gynecol. 1986;67:670–674
  33. Gibbons S, Martinez A, Schray M, et al. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1991;21:1019–1025
  34. Lim P, Al Kushi A, Gilks B, et al. Early stage uterine papillary serous carcinoma of the endometrium: Effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer. 2001;91:752–757
  35. Mallipeddi P, Kapp DS, Teng NN. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer. 1993;71:3076–3081
  36. Smith RS, Kapp DS, Chen Q, et al. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48:767–778
  37. Klaassen D, Shelley W, Starreveld A, et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: A National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol. 1988;6:1254–1263
  38. Klaassen D, Starreveld A, Shelly W, et al. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. A National Cancer Institute of Canada Clinical Trials Group Report. Int J Radiat Oncol Biol Phys. 1985;11:1801–1804
  39. Varia MA, Stehman FB, Bundy BN, et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:2849–2855

 All research was conducted at the Indiana University Simon Cancer Center, Indianapolis, IN.

PII: S1538-4721(08)00682-X

doi: 10.1016/j.brachy.2008.10.005

Brachytherapy
Volume 9, Issue 1 , Pages 61-65 , January 2010

Article Tools

* Image Usage & Resolution